CLAIMS

1. An isolated antibody comprising a mature heavy chain variable region comprising the three Kabat CDRs of SEQ ID NO:10, and being at least 95% identical to SEQ ID NO:10, and a light chain comprising the three Kabat CDRs of SEQ ID NO:5, and being at least 95% identical to SEQ ID NO:5.

2. The antibody of claim 1, wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:10 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:5.

3. The antibody of claim 1, wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:10 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:3;

or wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:8 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:3;

or wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:8 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:4;

or, wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:8 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:5;

or wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:9 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:3;

or wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:9 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:4,

or wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:10 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:4;

or wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:11 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:3;

or wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:11 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:4;

or wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:11 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:5.

4. The antibody of claim 1, wherein the mature heavy chain variable region has an amino acid sequence at least 99% identical to SEQ ID NO:10 and the mature light chain variable region has an amino acid sequence at least 99% identical to SEQ ID NO:5.

5. The antibody of any one of the preceding claims, wherein position L36 (Kabat numbering) is occupied by F and position L83 (Kabat numbering) is occupied by L and position H73 (Kabat numbering) is occupied by D.

6. The antibody of any one of the preceding claims, wherein the mature heavy chain variable region is fused to a heavy chain constant region and the mature light chain constant region is fused to a light chain constant region.

7. The antibody of claim 6, wherein the heavy chain constant region has the amino acid sequence designated SEQ ID NO:14 provided the C-terminal lysine residue may be omitted, and the light chain constant region has the amino acid sequence designated SEQ ID NO:13 or SEQ ID NO:28.

8. The antibody of claim 6, wherein the heavy chain constant region is a mutant form of natural human constant region which has reduced binding to an Fcγ receptor relative to the natural human constant region.

9. The antibody of claim 6, wherein the heavy chain constant region is of human IgG1 isotype.

10. A recombinant nucleic acid construct encoding a mature heavy chain variable region and/or a mature light chain variable region as defined by any one of the preceding claims, and a heterologous promoter.

11. The nucleic acid of claim 10 having a sequence comprising any one of SEQ ID NO:15, 17, 18, 19, and 20.

12. A pharmaceutical composition comprising an antibody as defined by any one of claims 1-9.

13. Use of the antibody as defined by any one of claims 1-9 in the preparation of a medicament for:

a) treating a patient having or at risk of a synucleinopathy; or

b) reducing Lewy body formation in a patient having or at risk of a Lewy body disease; or

c) inhibiting synuclein aggregation or reducing Lewy bodies or synuclein aggregates in a patient having or at risk of a Lewy body disease.